NAMS — NewAmsterdam Pharma NV Balance Sheet
0.000.00%
Last trade - 00:00
- $1.73bn
- $1.25bn
- $14.09m
2020 December 31st | 2021 December 31st | R2022 December 31st | 2023 December 31st | |
---|---|---|---|---|
Period Length: | — | — | — | — |
Source: | PROSPECTUS | PROSPECTUS | 10-K | 10-K |
Standards: | IFRS | IFRS | USG | USG |
Status: | fx Final | fx Final | Final | Final |
Cash | ||||
Cash and Equivalents | ||||
Cash and Short Term Investments | 9.6 | 60.4 | 468 | 340 |
Net Total Receivables | 0 | 4.88 | 2.07 | 1.88 |
Prepaid Expenses | ||||
Total Current Assets | 11.3 | 66.9 | 478 | 347 |
Gross Property, Plant And Equipment | ||||
Accumulated Depreciation | ||||
Net Property, Plant And Equipment | 0.015 | 0.216 | 0.154 | 0.101 |
Net Intangible Assets | ||||
Long Term Notes Receivable | ||||
Other Long Term Assets | ||||
Total Assets | 11.3 | 68 | 478 | 347 |
Accounts Payable | ||||
Payable / Accrued | ||||
Accrued Expenses | ||||
Notes Payable / Short Term Debt | ||||
Current Portion of Long Term Debt / Capital Leases | ||||
Total Other Current Liabilities | ||||
Total Current Liabilities | 15.6 | 11.2 | 36.1 | 49.9 |
Capital Lease Obligations | ||||
Total Long Term Debt | ||||
Total Debt | ||||
Total Other Liabilities | ||||
Total Liabilities | 15.6 | 11.4 | 48.4 | 58.7 |
Common Stock | ||||
Additional Paid In Capital | ||||
Retained Earnings (Accumulated Deficit) | ||||
Other Equity | ||||
Total Equity | -4.37 | 56.6 | 430 | 288 |
Total Liabilities & Shareholders' Equity | 11.3 | 68 | 478 | 347 |
Total Common Shares Outstanding |